# Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults.

- **DOI:** [10.1038/s41467-026-71448-2](https://doi.org/10.1038/s41467-026-71448-2)
- **Rating:** Limited (2.9 out of 5)
- **Verdict:** Remote fingerprick sampling shows feasible biomarker collection and venous concordance, but cross-sectional, internally inconsistent threshold analyses do not establish AD-risk triage.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41467-026-71448-2

## Key claims

1. these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people
   - Support: Tentative
   - Type: Primary finding
   - Basis: strong venous correlations in 40 participants but modest, unadjusted cognitive associations in a compositionally heterogeneous cohort
   - Location: Abstract
2. They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD.
   - Support: Tentative
   - Type: Secondary
   - Basis: cross-sectional threshold analyses lack pathology or longitudinal outcomes and contain unresolved subgroup inconsistencies
   - Location: Abstract
3. The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217.
   - Support: Tentative
   - Type: Secondary
   - Basis: limited cross-sectional evidence from self-reported cardiovascular history does not test whether the biomarkers differ
   - Location: Abstract
4. Patient feedback indicates high acceptability and usability of the capillary test method, giving confidence in the feasibility of this technology.
   - Support: Tentative
   - Type: Secondary
   - Basis: feedback came from kit completers after 23% non-completion, and qualitative methods were not described
   - Location: Abstract
5. Capillary p-tau217 significantly correlated with episodic memory (r = 0.299, P < 0.001), attention (r = 0.197, P = 0.019) and executive function (r = 0.191, P = 0.021).
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported rank correlations support the stated associations, though they are modest and unadjusted
   - Location: Results, Table 1

## Strengths

- **Remote collection tested under home conditions** Participants completed fingerprick collection without supervision and returned samples by post, directly examining an important practical step beyond clinic-based self-testing.
  - Dimension: contribution
  - Location: Methods, Blood Biomarker Collection; Results, Figure 1
- **Venous comparison supports concurrent measurement** Capillary and venous p-tau217 and GFAP were strongly correlated in the 40-participant subgroup, providing an initial concurrent-validity signal for remotely collected samples.
  - Dimension: methodological rigour
  - Location: Results, Correlation Between Plasma and Capillary Blood Biomarkers
- **Concrete triage pathways are identified** The Discussion distinguishes triage from diagnosis and identifies community assessment, primary-care monitoring, and clinical-trial pre-screening as intended pathways.
  - Dimension: application pathway
  - Location: Discussion, paragraphs 3–4 and final paragraph

## Limitations

- **Threshold counts and provenance conflict** The reported p-tau217-positive and double-positive counts do not reconcile with the available sample and Table 4. Methods says ROC analyses defined the thresholds in this cohort, while Results calls them pre-specified, undermining the central triage analyses.
  - Dimension: methodological rigour
  - Location: Results, threshold analysis and Table 4; Methods, Statistical Analysis
- **Primary associations lack confounding control** Biomarker–cognition correlations pool healthy and dementia groups recruited through different pathways without adjustment for age, diagnosis, or recruitment source. Between-group composition may therefore contribute to the reported associations.
  - Dimension: methodological rigour
  - Location: Methods, Recruitment and Statistical Analysis; Results, Table 1
- **Clinical-risk wording exceeds the design** The cross-sectional study has no AD-pathology reference standard or longitudinal outcome, yet the Abstract says the approach can identify people with the highest AD risk. Dementia discrimination is modest, with AUCs of 0.656 and 0.688.
  - Dimension: reporting
  - Location: Abstract; Results, Figure 2

## Reliability checks

Concerns (4 of 4 checks).

- **Results check:** Concern
  - They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD: "These values identified 46 (26%) and 29 (17%) participants using the p-tau217 and GFAP thresholds, respectively." (Results, threshold analysis) vs "Table 4GFAP and -tau217 status of participants with available data for both biomarkersBiomarker status% ParticipantsGFAP Positive + p-tau217 positive8.3GFAP positive + p-tau217 negative11.9GFAP negative + p-tau217 positive16.7GFAP negative + p-tau217 negative62.9" (Results, Table 4). Table 4 gives 8.3% + 16.7% = 25.0% p-tau217-positive, whereas the reported 46 positives among the 143 participants with p-tau217 data give 32.17%; because GFAP was available for everyone, restricting to participants with both biomarkers does not explain this difference. → Changes the size materially
  - The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217: "only 11 participants (6%) were positive for both capillary GFAP and p-tau217." (Results, Relationship Between Capillary p-tau217 and GFAP) vs "Biomarker status% ParticipantsGFAP Positive + p-tau217 positive8.3" (Results, Table 4). The 11 double-positive participants are 6.32% of the full cohort of 174 and 7.69% of the 143 participants with both biomarkers, so changing the denominator explains the narrative's rounded 6% but does not reproduce Table 4's 8.3%. → Conclusion holds
  - these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people: "IQCODE (r = 0.244, P < 0.001)" (Results, Correlation Between P-tau217 and GFAP with Cognition and Function) vs "p-tau217 data were available for 143 participants" (Results, Cohort Characterisation). Assuming all 143 available p-tau217 observations entered this correlation and using the conventional t approximation for Spearman's correlation, t = 0.244 × sqrt(141/(1 − 0.244²)) = 2.988 with 141 degrees of freedom gives a two-sided p approximately 0.0033; the actual pairwise sample size and tie structure are not reported. → Conclusion holds
  - The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217: "there was a non-significant 69% increase in the likelihood of GFAP-positive individuals having a history of hypertension" (Results, relationship with cardiovascular risk factors) vs "Hypertension24.6%35.7%1.32 (0.53 − 3.33)0.55" (Results, Table 5). The adjusted hypertension odds ratio of 1.32 corresponds to (1.32 − 1) × 100 = 32% higher odds, not 69%, while the printed unadjusted percentages imply a 45.12% relative increase in prevalence and also do not reproduce 69%. → Changes the size materially
- **Reporting and transparency:** Noted. The provenance of the 85%-specificity thresholds is reported inconsistently: Results calls them pre-specified, while Methods describes ROC analyses undertaken to define them.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared
- **Reference integrity:** Clean
  - 17 references in manuscript
  - 14 of 14 checkable references found in an index
  - 3 have no canonical index record — counted, but not index-checkable
  - 1 reference confirmed by manual review
  - 1 DOI points to a different paper:
    - #6 Cicognola, C. et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer’s Research & Therapy https://doi.org/10.1001/jamaneurol.2024. 3770 (2021). (DOI resolves to: “Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation” — Dubois, 2024 (JAMA Neurology)) https://doi.org/10.1001/jamaneurol.2024.3770
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
